Milestone Pharmaceuticals Inc. (MIST)
| Market Cap | 97.40M -47.1% |
| Revenue (ttm) | 2.34M |
| Net Income | -84.01M |
| EPS | -0.71 |
| Shares Out | 140.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 754,472 |
| Open | 0.6500 |
| Previous Close | 0.6444 |
| Day's Range | 0.6440 - 0.6960 |
| 52-Week Range | 0.6307 - 3.0600 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 5.57 (+705.99%) |
| Est. Earnings | Nov 11, 2026 |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MIST stock is "Strong Buy." The 12-month stock price target is $5.57, which is an increase of 705.99% from the latest price.
News
Milestone Pharmaceuticals price target lowered to $5 from $6 at Raymond James
Raymond James lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $5 from $6 and keeps a Strong Buy rating on the shares. Improving payer coverage above 50% and…
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovati...
Milestone Pharmaceuticals enrolls first European patient in ReVeRA-301 trial
Milestone Pharmaceuticals (MIST) announced that the first European patient has been enrolled in ReVeRA-301, its ongoing Phase 3 pivotal trial evaluating etripamil nasal spray for the treatment of atri...
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR Dutch Cardiovascular Investigator Network (WCN) Leads European ...
Milestone Pharmaceuticals management to meet virtually with Cantor
Virtual Meeting to be held on October 13-14 hosted by Cantor.
Milestone announces Montreal Heart Institute enrolled first patient
Milestone Pharmaceuticals (MIST) announced that the Montreal Heart Institute, recently activated as the first Canadian clinical trial site for the ReVeRA-301 Phase 3 trial evaluating etripamil nasal s...
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat...
Milestone Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
FDA approval and rapid launch of a new drug have led to positive provider feedback and growing patient momentum. Electrophysiologists are adopting quickly, and a phase III AFib trial is underway, leveraging prior experience. Cash runway extends into the second half of next year.
Milestone Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
CARDAMYST's launch shows strong early adoption by electrophysiologists and positive payer coverage. Efforts focus on expanding to cardiologists and boosting patient awareness. Revenue per script should rise as coverage grows and free drug programs taper. The pipeline includes a phase III AFib trial and global expansion.
Milestone Pharmaceuticals announces NMPA approval of etripamil for PSVT
Milestone Pharmaceuticals (MIST) announced that China’s National Medical Products Administration has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia in adul...
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat...
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes
MONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovati...
Milestone Pharmaceuticals enrolls first patient in ReVeRA-301 pivotal trial
Milestone Pharmaceuticals (MIST) announced that the first patient has been enrolled in the Phase 3 ReVeRA-301 pivotal trial evaluating etripamil for atrial fibrillation with rapid ventricular rate. Th...
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)
Cantor starts Milestone Pharmaceuticals at Overweight, sees 200% upside
Cantor Fitzgerald analyst Olivia Brayer initiated coverage of Milestone Pharmaceuticals (MIST) with an Overweight rating and $3 price target which offers 200% upside. The firm says improving access ca...
Milestone Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Milestone Pharmaceuticals (MIST) with an Overweight rating and $3 price target
Milestone Pharmaceuticals reports Q2 EPS (21c), consensus (19c)
Reports Q2 revenue $559,000, consensus $816,670. “We continue to make steady progress on the launch of CARDAMYST for PSVT supported by prescription growth from a widening base of new prescribers…
Milestone Pharmaceuticals Earnings Call Transcript: Q2 2026
CARDAMYST's first full commercial quarter saw rapid adoption, with over 1,200 prescriptions and more than 1,000 patients treated in Q2 2026. Commercial coverage expanded to over 50% post-quarter, and a pivotal phase III trial for AFib-RVR was initiated, supporting future growth.
Milestone Pharmaceuticals Quarterly report: Q2 2026
Milestone Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 12, 2026.
Milestone Pharmaceuticals Earnings release: Q2 2026
Milestone Pharmaceuticals released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Milestone Pharmaceuticals MD&A: Q2 2026
Milestone Pharmaceuticals filed a regulatory document on August 12, 2026 disclosing important business information.
Milestone Pharmaceuticals Report: Q2 2026
Milestone Pharmaceuticals published a report on August 12, 2026 containing material business information for investors and shareholders.
Milestone Pharmaceuticals Slides: Corporate presentation
Milestone Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray